Photodynamic therapy with verteporfin (Visudyne): impact on ophthalmology and visual sciences.

@article{Bressler2000PhotodynamicTW,
  title={Photodynamic therapy with verteporfin (Visudyne): impact on ophthalmology and visual sciences.},
  author={Neil M. Bressler and Susan B. Bressler},
  journal={Investigative ophthalmology & visual science},
  year={2000},
  volume={41 3},
  pages={624-8}
}
Recently, the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group reported that photodynamic therapy with verteporfin (Visudyne; Ciba Vision, Bülach, Switzerland) can reduce the risk of vision loss in patients with subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). This is a review of the circumstances leading to the design of the TAP Investigation, the findings of that investigation, and the impact of those findings… CONTINUE READING